DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma

Kenneth E. Fasanella, Alyssa Krasinskas, Karen E. Schoedel, Eizaburo Sasatomi, Adam Slivka, David C. Whitcomb, Michael Sanders, Laurentia Nodit, Stephen Raab, Kevin M. McGrath, N. Paul Ohori, Asif Khalid

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background/Aims: Preoperative distinction between pancreatic cancer (PC) and extrahepatic cholangiocarcinoma (CC) is desirable due to diverging management options, and to optimize enrollment into neoadjuvant trials. Methods: A single-center retrospective study of patients with PC or CC was undertaken. Four blinded pathologists reviewed all cases and reached a consensus diagnosis (PC or CC). Microdissection-based multiple microsatellite loss analysis and direct sequencing of K-ras oncogene was performed and compared for PC and CC. Results: Of 33 cases studied (17 males; 16 PC, 17 CC; 10 with primary sclerosing cholangitis), a K-ras mutation was present in 14/16 (87.5%) PC and 1/17 (5.9%) CC cases (p < 0.001), sensitivity and specificity were 87.5 and 94%, respectively. The mean fractional mutational rate was higher in PC (0.51; 95% CI 0.45-0.58) compared to CC (0.34; 95% CI 0.28-0.39, p < 0.001). Conclusions: The presence of a K-ras mutation in cytology specimens distinguishes PC from CC in this study.

Original languageEnglish (US)
Pages (from-to)429-433
Number of pages5
JournalPancreatology
Volume10
Issue number4
DOIs
StatePublished - Jan 1 2010

Fingerprint

Cholangiocarcinoma
Pancreatic Neoplasms
DNA
Sclerosing Cholangitis
Microdissection
Mutation
ras Genes
Microsatellite Repeats
Cell Biology
Retrospective Studies
Sensitivity and Specificity

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hepatology
  • Endocrinology

Cite this

Fasanella, K. E., Krasinskas, A., Schoedel, K. E., Sasatomi, E., Slivka, A., Whitcomb, D. C., ... Khalid, A. (2010). DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma. Pancreatology, 10(4), 429-433. https://doi.org/10.1159/000318807

DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma. / Fasanella, Kenneth E.; Krasinskas, Alyssa; Schoedel, Karen E.; Sasatomi, Eizaburo; Slivka, Adam; Whitcomb, David C.; Sanders, Michael; Nodit, Laurentia; Raab, Stephen; McGrath, Kevin M.; Ohori, N. Paul; Khalid, Asif.

In: Pancreatology, Vol. 10, No. 4, 01.01.2010, p. 429-433.

Research output: Contribution to journalArticle

Fasanella, KE, Krasinskas, A, Schoedel, KE, Sasatomi, E, Slivka, A, Whitcomb, DC, Sanders, M, Nodit, L, Raab, S, McGrath, KM, Ohori, NP & Khalid, A 2010, 'DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma', Pancreatology, vol. 10, no. 4, pp. 429-433. https://doi.org/10.1159/000318807
Fasanella KE, Krasinskas A, Schoedel KE, Sasatomi E, Slivka A, Whitcomb DC et al. DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma. Pancreatology. 2010 Jan 1;10(4):429-433. https://doi.org/10.1159/000318807
Fasanella, Kenneth E. ; Krasinskas, Alyssa ; Schoedel, Karen E. ; Sasatomi, Eizaburo ; Slivka, Adam ; Whitcomb, David C. ; Sanders, Michael ; Nodit, Laurentia ; Raab, Stephen ; McGrath, Kevin M. ; Ohori, N. Paul ; Khalid, Asif. / DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma. In: Pancreatology. 2010 ; Vol. 10, No. 4. pp. 429-433.
@article{33619ddc19844682a0fc3884d5254b4e,
title = "DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma",
abstract = "Background/Aims: Preoperative distinction between pancreatic cancer (PC) and extrahepatic cholangiocarcinoma (CC) is desirable due to diverging management options, and to optimize enrollment into neoadjuvant trials. Methods: A single-center retrospective study of patients with PC or CC was undertaken. Four blinded pathologists reviewed all cases and reached a consensus diagnosis (PC or CC). Microdissection-based multiple microsatellite loss analysis and direct sequencing of K-ras oncogene was performed and compared for PC and CC. Results: Of 33 cases studied (17 males; 16 PC, 17 CC; 10 with primary sclerosing cholangitis), a K-ras mutation was present in 14/16 (87.5{\%}) PC and 1/17 (5.9{\%}) CC cases (p < 0.001), sensitivity and specificity were 87.5 and 94{\%}, respectively. The mean fractional mutational rate was higher in PC (0.51; 95{\%} CI 0.45-0.58) compared to CC (0.34; 95{\%} CI 0.28-0.39, p < 0.001). Conclusions: The presence of a K-ras mutation in cytology specimens distinguishes PC from CC in this study.",
author = "Fasanella, {Kenneth E.} and Alyssa Krasinskas and Schoedel, {Karen E.} and Eizaburo Sasatomi and Adam Slivka and Whitcomb, {David C.} and Michael Sanders and Laurentia Nodit and Stephen Raab and McGrath, {Kevin M.} and Ohori, {N. Paul} and Asif Khalid",
year = "2010",
month = "1",
day = "1",
doi = "10.1159/000318807",
language = "English (US)",
volume = "10",
pages = "429--433",
journal = "Pancreatology",
issn = "1424-3903",
publisher = "S. Karger AG",
number = "4",

}

TY - JOUR

T1 - DNA mutational differences in cytological specimens from pancreatic cancer and cholangiocarcinoma

AU - Fasanella, Kenneth E.

AU - Krasinskas, Alyssa

AU - Schoedel, Karen E.

AU - Sasatomi, Eizaburo

AU - Slivka, Adam

AU - Whitcomb, David C.

AU - Sanders, Michael

AU - Nodit, Laurentia

AU - Raab, Stephen

AU - McGrath, Kevin M.

AU - Ohori, N. Paul

AU - Khalid, Asif

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Background/Aims: Preoperative distinction between pancreatic cancer (PC) and extrahepatic cholangiocarcinoma (CC) is desirable due to diverging management options, and to optimize enrollment into neoadjuvant trials. Methods: A single-center retrospective study of patients with PC or CC was undertaken. Four blinded pathologists reviewed all cases and reached a consensus diagnosis (PC or CC). Microdissection-based multiple microsatellite loss analysis and direct sequencing of K-ras oncogene was performed and compared for PC and CC. Results: Of 33 cases studied (17 males; 16 PC, 17 CC; 10 with primary sclerosing cholangitis), a K-ras mutation was present in 14/16 (87.5%) PC and 1/17 (5.9%) CC cases (p < 0.001), sensitivity and specificity were 87.5 and 94%, respectively. The mean fractional mutational rate was higher in PC (0.51; 95% CI 0.45-0.58) compared to CC (0.34; 95% CI 0.28-0.39, p < 0.001). Conclusions: The presence of a K-ras mutation in cytology specimens distinguishes PC from CC in this study.

AB - Background/Aims: Preoperative distinction between pancreatic cancer (PC) and extrahepatic cholangiocarcinoma (CC) is desirable due to diverging management options, and to optimize enrollment into neoadjuvant trials. Methods: A single-center retrospective study of patients with PC or CC was undertaken. Four blinded pathologists reviewed all cases and reached a consensus diagnosis (PC or CC). Microdissection-based multiple microsatellite loss analysis and direct sequencing of K-ras oncogene was performed and compared for PC and CC. Results: Of 33 cases studied (17 males; 16 PC, 17 CC; 10 with primary sclerosing cholangitis), a K-ras mutation was present in 14/16 (87.5%) PC and 1/17 (5.9%) CC cases (p < 0.001), sensitivity and specificity were 87.5 and 94%, respectively. The mean fractional mutational rate was higher in PC (0.51; 95% CI 0.45-0.58) compared to CC (0.34; 95% CI 0.28-0.39, p < 0.001). Conclusions: The presence of a K-ras mutation in cytology specimens distinguishes PC from CC in this study.

UR - http://www.scopus.com/inward/record.url?scp=77955614044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955614044&partnerID=8YFLogxK

U2 - 10.1159/000318807

DO - 10.1159/000318807

M3 - Article

VL - 10

SP - 429

EP - 433

JO - Pancreatology

JF - Pancreatology

SN - 1424-3903

IS - 4

ER -